You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞虹醫藥(688176.SH):APL-1702用於治療宮頸高級別鱗狀上皮內病變的國際多中心III期臨牀試驗已達到主要研究終點
格隆匯 01-31 07:44

格隆匯1月31日丨亞虹醫藥(688176.SH)近日在接待機構投資者調研時表示,APL-1702用於治療宮頸高級別鱗狀上皮內病變的國際多中心III期臨牀試驗已達到主要研究終點,並將在2024年歐洲生殖道感染和腫瘤研究協會會議(EUROGIN)大會上披露該項臨牀試驗的數據。

公司將積極與監管部門溝通遞交該藥品的新藥上市申請事宜,關於NDA的相關情況,公司將嚴格按照《上海證券交易所科創板股票上市規則》等相關規定履行信息披露義務。

目前針對宮頸癌前病變患者以傳統手術治療方法為主,最常見的治療方式包括宮頸環形電切術(LEEP)和冷刀錐形切除術(CKC),尚未有非手術治療產品上市。APL-1702未來會參考傳統手術治療的綜合費用、產品自身的創新性和藥物經濟學評價、患者支付能力等多方面因素進行定價。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account